Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.61 |
| ▸ | JAK3 | P52333 | 4/20 | 0.57 |
| ▸ | IKBKB | O14920 | 4/20 | 0.56 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.54 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519561 | 0.95 | JAK2 (0.59) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3519961 | 0.91 | JAK2 (0.57) | JAK2JAK3IKBKBCA12ABL1 | |
| SCHEMBL3520771 | 0.91 | JAK2 (0.58) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3520398 | 0.91 | JAK2 (0.57) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3518653 | 0.91 | IKBKB (0.59) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3520471 | 0.90 | IKBKB (0.59) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3516525 | 0.89 | EPHX2 (0.61) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3518248 | 0.88 | JAK2 (0.56) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3520074 | 0.87 | JAK2 (0.53) | JAK2JAK3IKBKBCHUKCA12 | |
| SCHEMBL3518274 | 0.86 | JAK2 (0.56) | JAK2JAK3IKBKBCA12ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | JAK2 341/4885JAK3 1251/4885IKBKB 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.